Results 31 to 40 of about 25,852 (227)

Combined intra-arterial chemotherapy and intravitreal melphalan for the treatment of advanced unilateral retinoblastoma [PDF]

International Journal of Ophthalmology, 2020
"AIM: To evaluate the efficacy and safety of combined intra-arterial chemotherapy (IAC) and intravitreal melphalan (IVM) for the treatment of advanced unilateral retinoblastoma.
Ting-Yi Liang, Xiu-Yu Zhu, Xu-Ming Hua, Xun-Da Ji, Pei-Quan Zhao   +4 more
doaj   +1 more source

L-Type Amino Acid Transporter-1 Overexpression and Melphalan Sensitivity in Barrett's Adenocarcinoma

Neoplasia: An International Journal for Oncology Research, 2004
The L-type amino acid transporter-1 (LAT-1) has been associated with tumor growth. Using cDNA microarrays, overexpression of LAT-1 was found in 87.5% (7/8) of esophageal adenocarcinomas relative to 12 Barrett's samples (33% metaplasia and 66% dysplasia ...
Jules Lin, Duna A. Raoof, Dafydd G. Thomas, Joel K. Greenson, Thomas J. Giordano, Gregory S. Robinson, Maureen J. Bourner, Christopher T. Bauer, Mark B. Orringer, David G. Beer   +9 more
doaj   +1 more source

Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. [PDF]

PLoS ONE, 2016
Previous NMR studies demonstrated that lonidamine (LND) selectively diminishes the intracellular pH (pHi) of DB-1 melanoma and mouse xenografts of a variety of other prevalent human cancers while decreasing their bioenergetic status (tumor βNTP/Pi ratio)
Kavindra Nath, David S Nelson, Mary E Putt, Dennis B Leeper, Bradley Garman, Katherine L Nathanson, Jerry D Glickson   +6 more
doaj   +1 more source

Ice-cream used as cryotherapy during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic stem cell transplantation

Scientific Reports, 2021
Oral mucositis (OM) is one of the most frequent adverse events of high-dose conditioning chemotherapy with melphalan prior to autologous hematopoietic stem cell transplantation (AHSCT). It significantly reduces the patients’ quality of life.
Marcin Jasiński, Martyna Maciejewska, Anna Brodziak, Michał Górka, Kamila Skwierawska, Wiesław W. Jędrzejczak, Agnieszka Tomaszewska, Grzegorz W. Basak, Emilian Snarski   +8 more
doaj   +1 more source

Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities

Oncology Reviews, 2012
Stem cell transplantation forms an integral part of the treatment for multiple myeloma. This paper reviews the current role of transplantation and the progress that has been made in order to optimize the success of this therapy.
Catriona Elizabeth Mactier, Md Serajul Islam   +1 more
doaj   +1 more source

Microrobotic Catheterization of the Ophthalmic Artery for Targeted Treatment of Retinoblastoma

Advanced Intelligent Systems, EarlyView.
A microrobotic platform is presented that allows teleoperated and autonomous navigation of flow‐driven magnetic microcatheters, MagFlow, into the ophthalmic artery for superselective intra‐arterial infusion of chemotherapy to treat retinoblastoma. Extensive benchtop validations with patient‐derived biomimetic phantoms under optical and fluoroscopic ...
Artur Banach, Mehdi Krichen, Julian Raub, Christina Stathopoulos, Bruno Bartolini, Mahmut Selman Sakar   +5 more
wiley   +1 more source

Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis

American Journal of Hematology, EarlyView.
ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM ...
Maximilian J. Steinhardt, Ute Hegenbart, Tamer Hellou, Sara Oubari, Murielle Roussel, Rahel Schwotzer, Francis Buadi, David Dingli, Moritz Binder, Taxiarchis Kourelis, Saurabh S. Zanwar, Max J. Rieger, Caroline Morbach, Vladimir Cejka, Bernhard Gerber, Stefan Störk, Hermann Einsele, Shaji Kumar, Morie Gertz, Alexander Carpinteiro, K. Martin Kortum, Eli Muchtar, Angela Dispenzieri, Stefan Schönland   +23 more
wiley   +1 more source

Melphalan improves toxicity of arsenic trioxide in adult T-cell leukemia/lymphoma cells

Biochemistry and Biophysics Reports
Adult T-cell leukemia/lymphoma (ATLL) is a hematologic neoplasm with poor prognosis. Melphalan is an alkylating anti-cancer agent, and arsenic trioxide (ATO) is routine chemotherapy drug for ATLL with low response rate.
Faeze Khodadadi, Mohammad Hadi Sadeghian, Zahra Delbari, Mohadese Kazemi, Hamide Koohpaykar, Fatemeh B. Rassouli   +5 more
doaj   +1 more source

Adsorption of melphalan anticancer drug on the surface of fullerene (C24): a comprehensive DFT study [PDF]

Nanomedicine Journal, 2019
Objective (s): The present study aimed to assess the adsorption of fullerene C24 with Melphalan anticancer agent in a solvent phase (water) at the B3LYP/6-31G (d) theoretical level.Materials and Methods: Initially, the structures of Melphalan and ...
Elaheh Sadat Mirkamali, Roya Ahmadi, Khadijah Kalateh, Goldasteh Zarei   +3 more
doaj   +1 more source

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)

American Journal of Hematology, EarlyView.
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María‐Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld   +25 more
wiley   +1 more source